Related Experiment Video
Updated: Aug 11, 2026

Analysis of Cell Cycle Position in Mammalian Cells
Published on: January 21, 2012
The INK4a/ARF tumor suppressor: one gene--two products--two pathways
L Chin1, J Pomerantz, R A DePinho
1Dept of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
Cancer cells inactivate the retinoblastoma (RB) and p53 pathways, disrupting cell-cycle regulation and apoptosis. The INK4a/ARF locus is key, producing p16INK4a and p19ARF proteins that control these critical tumor suppressor pathways.
Area of Science:
- Molecular Biology
- Cancer Biology
- Genetics
Background:
- Cancer cells frequently inactivate the retinoblastoma (RB) and p53 tumor suppressor pathways.
- This inactivation leads to uncontrolled cell division and evasion of programmed cell death (apoptosis).
- Understanding the molecular mechanisms governing these pathways is crucial for cancer research.
Purpose of the Study:
- To investigate the role of the INK4a/ARF locus in regulating the RB and p53 pathways.
- To elucidate how the dual products of INK4a/ARF contribute to tumor suppression.
- To establish the significance of INK4a/ARF in the context of tumorigenesis.
Main Methods:
- Analysis of the INK4a/ARF locus and its gene products.
- Investigation of p16INK4a function in relation to the RB pathway.
- Examination of p19ARF function in relation to the p53 pathway.
Main Results:
- The INK4a/ARF locus generates two distinct proteins: p16INK4a and p19ARF.
- p16INK4a acts as a cyclin-dependent kinase inhibitor, functioning upstream of the RB pathway.
- p19ARF inhibits MDM2, thereby preventing the degradation of p53.
- This single gene locus thus influences both the RB and p53 tumor suppressor pathways.
Conclusions:
- The INK4a/ARF locus is a critical hub integrating the RB and p53 tumor suppressor pathways.
- Its ability to produce two distinct proteins, p16INK4a and p19ARF, highlights its central role in cell-cycle control and apoptosis.
- The functional inactivation of INK4a/ARF is a common event in tumorigenesis, underscoring its importance in cancer development.
Related Concept Videos
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...

